In turn the aberrant IGF1R-signaling favors the generation of primitive cancer stem cells and EMT, whereas IGF1R-inhibitors can revert these phenomena, thus, targeting IGF1R may have the potential to prevent hypoxia-induced cancer progression, EMT and ultimately TKI-resistance [234,235,236]. This evidence concerns the gene IGF1R and cancer.